Hemogenyx Pharmaceuticals (LSE:HEMO) ROCE %: -414.90% (As of Dec. 2025)


LSE:HEMO Hemogenyx Pharmaceuticals PLC LSE:HEMO
31 GF Score
Price £7.63
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals ROCE %?

Hemogenyx Pharmaceuticals LSE:HEMO -2.24% 31 ROCE % is -414.90% as of Dec. 2025. GuruFocus rates LSE:HEMO with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hemogenyx Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was -414.90%.

Hemogenyx Pharmaceuticals  (LSE:HEMO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hemogenyx Pharmaceuticals ROCE % Related Terms

Hemogenyx Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals ROCE % Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.52 -54.95 -108.99 -127.22 -331.24

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.15 -97.98 -124.58 -404.64 -414.90
LSE:HEMO
31GF Score
Hemogenyx Pharmaceuticals PLC LSE:HEMO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals ROCE % Calculation

Hemogenyx Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-9.538/( ( (4.212 - 1.159) + (4.176 - 1.47) )/ 2 )
=-9.538/( (3.053+2.706)/ 2 )
=-9.538/2.8795
=-331.24 %

Hemogenyx Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-9.302/( ( (3.101 - 1.323) + (4.176 - 1.47) )/ 2 )
=-9.302/( ( 1.778 + 2.706 )/ 2 )
=-9.302/2.242
=-414.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -414.90% mean?
Hemogenyx Pharmaceuticals (LSE:HEMO) has a ROCE % of -414.90% as of Dec. 2025.
Is Hemogenyx Pharmaceuticals' ROCE % too high?
Hemogenyx Pharmaceuticals' current ROCE % is -414.90%. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' ROCE % compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' ROCE % of -414.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Hemogenyx Pharmaceuticals's current ROCE % is -414.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (LSE:HEMO) has a current ROCE % of -414.90%. The current ROCE % is -414.90%. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (LSE:HEMO), the current ROCE % is -414.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for LSE:HEMO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£7.63
Price